Download Invited Speaking Engagements, Presentations, Symposia

Brian Shuch, MD
CURRICULUM VITAE
Date: September 21th, 2016
Name:
Brian Shuch, M.D.
Appointment:
Assistant Professor, Department of Urology and Radiology
Term:
On a continuing basis beginning January 1, 2013
School:
Yale University School of Medicine
Education
B.S.
M.D.
Certificate
University of Michigan
New York University School of Medicine
Translational Investigation, NIH K30 Program/UCLA
2000
2004
2007-2008
Career/Academic Appointments:
2013 – Present Assistant Professor, Yale Departments of Urology and Diagnostic Radiology
2010-2013
Urologic Oncology Fellow, National Cancer Institute
2005-2010
UCLA School of Medicine, Urology Resident
2004-2005
UCLA School of Medicine, General Surgery Intern
Board Certification
Board Certified
2015
Professional Honors & Recognition
International/National/Regional:
2013
ASCO Foundation Merit Award
2012
ASCO Foundation Merit Award
2010-2013: NIH General Loan Repayment Program Awardee
2009
Longmire Surgical Society Award
2009
ASCO Foundation Merit Award
2008
Longmire Surgical Society Award
2008
ASCO Foundation Merit Award
2004
Valentine Mott Award for Excellence in Urology
1996
Phillips-Magnavox Laboratories, Second Place Essay Contest Winner
University:
2004
Alpha Omega Alpha National Honor Society
2004
Joseph Collins Foundation/Augustus Landis Packer Award for most outstanding
graduating 4th year NYU Medical Student
2001
New York University Presidential Service Award
1998-2000 University of Michigan, Class Honors
1998-2000 O’Leary Scholarship for Excellence in Natural Sciences
1999-2000 Angell Scholar, (4.0 g.p.a. - 3 consecutive semesters)
School of Medicine:
1
Brian Shuch, MD
2009
2003
UCLA Urology Guy Della Riva Award
NYU Medicine Clerkship Award: Pathophysiology
Invited Speaking Engagements, Presentations, Symposia & Workshops Not Affiliated With Yale:
International/National
2016
Food and Drug Administration RCC Mini-Symposium, “Neoadjuvant vs. Adjuvant
Approaches in Length of Therapy Beyond Surgery.”
2016
15th International Kidney Cancer Symposium, “Developments in Non-Clear Cell RCC
Biology.”
2016
SWOG GU Cancer Survivorship Committee: “A Phase III Trial of Renal Mass Biopsy
in Early Stage Kidney Cancer. ” (Spring Meeting)
2016
SWOG Symposium: The Role of Cytoreductive Surgery in Metastatic Genitourinary
Cancers, “Translational Medicine and Cytoreductive Nephrectomy Trials.” (Spring
Meeting)
2016
SWOG GU Trial Committee: “A Phase III Trial of Renal Mass Biopsy in Early Stage
Kidney Cancer. ” (Winter Meeting)
2016
SWOG GU Trial Committee: “BIQSFP Grant Application for Translational
Correlatives on S1500: PAPMET trial” (Winter Meeting)
2016
Dana Farber Renal Spore Symposium, “Genomic Characterization of Sarcomatoid
Transformation in Clear Cell Renal Cell Carcinoma.”
2016
ASCO GU Cancer Symposium, “Best of Journals: Renal Cell Carcinoma”
2015
SWOG GU Trial Committee: “Translational Correlatives on S1500: PAPMET trial”
2015
14th International Kidney Cancer Symposium, “Multi-disciplinary Kidney Tumor
Board”
2015
Sixth BHD Symposium and First International Upstate Kidney Cancer Symposium,
“Update of the Management of Non-Clear Cell Kidney Cancer”
2015
AUA 2015 National Meeting, Engineering and Urology Society, “What’s new and on
the horizon for percutaneous renal ablation.”
2014
SWOG GU Trial Committee: “A randomized, phase II efficacy assessment of multiple
MET/HGF inhibitors in metastatic papillary renal carcinoma (PAPMET)”
2014
13th International Kidney Cancer Symposium: “Management of Kidney Cancer in
Young Patients”
2014
National Society of Genetic Counselors Webinar: “Diagnosis and Management of
Hereditary Kidney Cancer Syndromes”
2013
12th Annual Kidney Cancer Symposium: “Surgery in the Setting of Metastatic Disease”
2013
ASCO GU Cancer Symposium: “Defining Early-Onset Kidney Cancer: Implications
for Age-Based Genetic Counseling”
2011
Society of Urologic Oncology Winter Meeting 2011: “Adrenal Hyperplasia as part of
the Hereditary Leiomyomatosis and Renal Cell Cancer Phenotype.”
2009
ASCO GU Cancer Symposium “Cytoreductive Nephrectomy for Patients with
Advanced Kidney Cancer and Sarcomatoid Histology.”
2008
ASCO GU Cancer Symposium: “Brain Metastasis from Renal Cell Carcinoma:
Presentation, Recurrence, and Survival.”
Peer-Reviewed Presentations & Symposia Given at Meetings Not Affiliated With Yale
2
Brian Shuch, MD
Regional
2015
2009
2008
New York Medical College Grand Rounds, “Racial Disparities in Renal Cell
Carcinoma.”
UCLA Longmire Surgical Society: “Histologic Evaluation of Metastases in Renal Cell
Carcinoma with Sarcomatoid Transformation and its Implications for Systemic
Therapy.”
UCLA Longmire Surgical Society: “Brain Metastasis from Renal Cell Carcinoma:
Presentation, Recurrence, and Survival.”
Professional Service
Peer Review Groups/Grant Study Sections
Journal Services
Editorial Board
2014-present Canadian Journal of Urology
2016-present Journal of Onco-nephrology
2016-present Kidney Cancer
Reviewer
2015-present
2014-present
2014-present
2012-present
2011-present
2011-present
2011-present
2011-present
PLOS One
Clinical Cancer Research
European Urology
Journal of Urology
Urologic Oncology
Annals of Surgical Oncology
British Journal of Urology International
Cancer Epidemiology, Biomarkers, and Prevention
Professional Service for Professional Organizations
NCCN Guideline Panel, Kidney and Testicular Cancers
Clinical Advisory Counsel/Kidney Cancer Working Group, VHL Family Alliance
Editorial Board, NCI Physicians Data Query (PDQ®) for Cancer Genetics and Kidney Cancer
Manuscript Coordinator, Chromophobe Kidney Cancer Project, The Cancer Genome Atlas
Biospecimen Working Group, Papillary Kidney Cancer Project, The Cancer Genome Atlas
SWOG, Genitourinary Clinical Trial Committee
Society of Urologic Oncology Clinical Trial Consortium, Renal Cancer Group
Member, AACR
Member, ASCO
Member, SUO
Member, AUA
President, Alpha Omega Alpha National Honor Society, NYU Class of 2004
President, NYU School of Medicine Student Council, 2001-02
Vice-President, NYU Medical School Class of 2004, 2000-01
Chief Presidential Advisor, Medical School Student Council, 2002-2004
University Committee on Student Life, Medical School Representative, 2001-02
NYU Dean's Committee on Residential Environment, 2000-04
Professional Service at Yale
Director of Genitourinary Biospecimen Repository 2013-Present
3
Brian Shuch, MD
Yale Cancer Center Data Safety Monitoring Committee 2015-Present
Course Director Urology Grand Rounds 2016
Co-Director Medical Student GU Tumor Lab, 2016
Enhanced Recovery After Surgery (ERAS) Committee for Urology 2016
Director, GU Cancer Program, Yale Cancer Genetics & Prevention Program 2015-Present
Director of Renal Cancer Tumor Board 2014-Present
Schwartz Rounds Planning Committee 2014-Present
Clinical Trials Strategic Planning Committee 2015
Oral Chemotherapy Task Force 2014
Emotional Distress Thermometer Team 2014
Bibliography (Total of 106 Manuscripts)
Peer Reviewed Original Research:
1. Shuch B, Mikhail M, Satagopan J, Lee P, Yee H, Chang C, Cordon-Cardo C, Taneja SS, Osman
I. Racial disparity of epidermal growth factor receptor expression in prostate cancer. J Clin Oncol,
2005, 23 (1) 248.
2. Osman I, Mikhail M, Shuch B, Clute M, Cheli CD, Ghani F, Thiel RP, Taneja SS. Serum levels
of shed Her2/neu protein in men with prostate cancer correlate with disease progression. J Urol.
2005, 174:2174-7.
3. Klatte T, Pantuck AJ, Riggs SB, Kleid MD, Shuch B, Zomorodian N, Kabbinavar FF, Belldegrun
AS. Prognostic Factors for Renal Cell Carcinoma With Tumor Thrombus Extension. J Urol.
2007, 178:1189-1195.
4. Shuch, B, Riggs, SB, La Rochelle, J, Kabbinavar, FF, Avakian, R, Pantuck, AJ, Patard, JJ,
Belldegrun, AS. Neoadjuvant Targeted Therapy and the Future of Surgical Management of
Advanced Kidney Cancer: Clinical Observations and Implications for a New Treatment
Paradigm, BJU Int., 2008, 102:692-6.
5. Belldegrun, AS, Klatte, T, Shuch B, La Rochelle, JC, Miller, DC, Said, JW, Riggs, SB,
Zomorodian, Kabbinavar, FF, deKernion, JB, Pantuck, AJ. Cancer-specific survival outcomes
among patients treated during the cytokine era of kidney cancer (1989-2005): A benchmark for
emerging targeted cancer therapies. Cancer, 2008, 113(9):2457-2463.
6. Shuch, B, La Rochelle, JC, Klatte, T, Riggs, S, Liu, W, Kabbinavar, F, Pantuck, AJ, Belldegrun,
AS, Brain Metastasis from Renal Cell Carcinoma: Presentation, Recurrence, and Survival.
Cancer, 2008, 113(7):1641-8.
7. Shuch, B, La Rochelle, JC, Wu, J, Klatte, T, Riggs, SB, Kabbinavar, F, Belldegrun, AS, Pantuck
AJ, Performance Status and Cytoreductive Nephrectomy: Redefining Management in Patients
with Poor Performance. Cancer. 2008, 113(6):1324-31.
8. La Rochelle, JC, Shuch, B, Riggs, SB, Liang, LJ, Sadat, A, Kabbinavar, FF, Pantuck, AJ,
Belldegrun, AS, Partial nephrectomy in solitary kidneys: long-term renal function and local
recurrence outcomes. J Urol. 2009, 181(5):2037-42.
9. Shuch, B, Said, JW, LaRochelle, JC, Zhou, Y, Li, G, Klatte, T, Kabbinavar, FF, Pantuck, AJ,
Belldegrun, AS. Cytoreductive Nephrectomy for Patients with Advanced Kidney Cancer and
Sarcomatoid Histology: Is Upfront Resection Indicated, Avoidable, and is there an Alternative? J
Urol. 2009, 185: 2164-71.
10. Klatte T, Said JW, de Martino M, Larochelle J, Shuch B, Rao JY, Thomas GV, Kabbinavar FF,
Belldegrun AS, Pantuck AJ. Presence of Tumor Necrosis is Not a Significant Predictor of
4
Brian Shuch, MD
Survival in Clear Cell Renal Cell Carcinoma: Higher Prognostic Accuracy of Extent Based Rather
Than Presence/Absence Classification. J Urol, 2009, 181(4):1558-64.
11. Klatte, T, Pantuck, AJ, Said, JW, Seligson, DB, Rao, NP, La Rochelle, JC, Shuch, B, Zisman, A,
Kabbinavar, FF, Belldegrun, AS, Cytogenetic and molecular tumor profiling distinguish type 1
and type 2 papillary renal cell carcinoma. Clinical Cancer Research, 2009, 15:1162-9.
12. Klatte T, Seligson DB, Larochelle J, Shuch B, Said JW, Riggs SB, Zomorodian N, Kabbinavar
FF, Pantuck AJ, Belldegrun AS. Molecular signatures of localized clear cell renal cell carcinoma
to predict disease-free survival after nephrectomy, Cancer Epidemiology, Biomarkers &
Prevention, 2009, 18:894-900
13. Shuch, B, La Rochelle, JC, Okyia, T, Pantuck, AJ, Vallera, C, Smith, RB, Belldegrun, AS,
Intraoperative Thrombus Embolization During Nephrectomy and Tumor Thrombectomy: Critical
Analysis of the UCLA Experience, J Urol, 2009;181(2):492-8
14. Klatte, T, Rao, N, de Martino, M, LaRochelle, J, Shuch, B, Zomorodian, N, Said, J, Kabbinavar,
FF, Belldegrun, AS, Pantuck AJ, Cytogenetic profile predicts prognosis of patients with clear cell
renal cell carcinoma, Journal of Clinical Oncology, 2009; 10;27(5):746-53.
15. Klatte, T, Pantuck, AJ, Said, JW, Seligson, DB, Rao, NP, LaRochelle, JC, Shuch, B, Zisman, Z,
Kabbinavar, FF, Belldegrun, AS: Cytogenetic and molecular profiling for type 1 and type 2
papillary renal cell carcinoma. Clinical Cancer Research, 2009, 15(4):1162-9.
16. de Martino M, Klatte T, Seligson DB, LaRochelle J, Shuch B, Caliliw R, Li Z, Kabbinavar FF,
Pantuck AJ, Belldegrun AS. CA9 gene: single nucleotide polymorphism predicts metastatic renal
cell carcinoma prognosis. J Urol. 2009. 182(2):728-34.
17. Shuch, B, Said, JW, LaRochelle, JC, Zhou, Y, Li, G, Klatte, T, Pouliot, F, Kabbinavar, FF,
Belldegrun, AS, Pantuck, AJ Histologic Evaluation of Metastases in Renal Cell Carcinoma with
Sarcomatoid Transformation and its Implications for Systemic Therapy. Cancer. 2010.
116(3):616-24
18. Karnwal, A, Venegas, R, Reznicheck, R, Shuch, B, Bassett, J, Rajfer, J. The role of fluorescence
in situ hybridization assay in the surveillance of non-muscle-invasive bladder cancer. Can J Urol.
2010. 17 (2):5077-81.
19. LaRochelle, J, Klatte, T, Dastane, A, Rao, N, Seligson, D, Said, J, Shuch, B, Zomorodian, N,
Kabbinavar, F, Belldegrun, AS, Pantuck AJ, Chromosome 9p deletions identify an aggressive
phenotype of clear cell renal cell carcinoma. Cancer. 2010. 116(20):4696-702.
20. Shuch, B, Crispen, PL, Leibovich, BC, La Rochelle, JC, Pouliot, F, Pantuck, AJ, Liu, W, Crepel,
M, Schuckman, A, Rigaud, J, Bouchot, O, Patard, JJ, Skinner, D, Belldegrun, AS, Blute, BM.
Cardiopulmonary bypass and RCC with level IV tumor thrombus: Can deep hypothermic
circulatory arrest limit perioperative mortality? BJUI. 2011.107(5):724-8.
21. Pouliot, F, Pantuck A, Imbeault, A, Shuch B, Calimlim, B, Audet, JF, Finley, DS, Dujardin, T.
Multivariate analysis of the factors involved in loss of renal differential function after
laparoscopic partial nephrectomy: a role for warm ischemic time. Can Urol Assoc J. 2011,
5(2):89-95.
22. Imbeault, A, Pouliot, F, Finley, D, Shuch, B, Dujardin, T. Prospective study comparing two
techniques of renal clamping in laparoscopic partial nephrectomy: Impact on perioperative
parameters. J of Endourology. 2011, 5(2):89-95.
23. Klatte, T, Said, JW, Seligson, DB, Rao, N, de Martino, M, Shuch, B, Zomorodian, N,
Kabbinavar, FF, Belldegrun, AS, Pantuck AJ. Pathological, immunohistochemical and
cytogenetic features of papillary renal cell carcinoma with clear cell features. J Urol. 2011. 185
(1):30-5.
5
Brian Shuch, MD
24. Shuch, B, Belldegrun, A, Said, J, Pantuck, AJ, Saigal, C. Quality of RCC Pathologic Reporting:
Implications for Systemic Therapy, Prognostication, and Surveillance. BJUI. 2011.108(3):343-8.
25. Finley, DS, Shuch, B, Said, J, Castor, B, Sadaat, A, Elashoff, D, Magyar, C, Zhang, Z,
Kabbinavar, F, Belldegrun, A, Pantuck A. External Validation of the Chromophobe Tumor
Grading System. J Urol. 2011,186(6):2168-74.
26. Shuch, B, Bratslavsky, G, Shih, J, Vourganti, S, Finley, D, Castor, B, Treat, E, Linehan, WM,
Pantuck, AJ, Said, J, Belldegrun, AS. Impact of Pathologic Tumor Characteristics in Patients with
Sarcomatoid Renal Cell Carcinoma, BJUI. 2012, 109(11):1600-6.
27. Shuch, B, Vourganti, S, Friend, J, Zehngebot, L, Linehan, W.M., Srinivasan, R. Targeting the
mTOR pathway in Chromophobe Kidney Cancer. Journal of Cancer. 2012, 3:152-157.
28. Hofmann, JN, Schwartz, K, Chow, WH, Ruterbusch, JJ, Shuch B, Karami, S, Linehan WM,
Rothman, N, Wacholder, S, Graubard, BI, Colt, JS, Purdue, M. The association between chronic
renal failure and renal cell carcinoma may differ between black and white Americans. Cancer
Causes Control. 2012, 24(1):167-74
29. Shuch, B*, Ricketts, C*, Vocke, C, Metwalli, AR, Bratslavsky, G, Middelton, L, Pautler, SE,
Peterson, J, Stolle, CA, Zbar, B, Merino, MJ, Schmidt, LS, Pinto, PA, Srinivasan, R, Pacak, K,
Linehan, WM. Clinical Features and Management of Succinate Dehydrogenase Renal Cell
Carcinoma (SDH-RCC), J Urol. 2012, 188(6):2063-2071.
30. Chow, WH, Shuch, B, Linehan, WM, Devesa, S. Racial disparity in renal cell carcinoma patient
survival according to demographic and clinical characteristics, Cancer, 2013, 15;119(2):388-94.
31. Purdue, MP, Moore, LE, Merino, MJ, Boffetta, P, Colt, JS, Schwartz, KL, Bencho, V, Davis, FG,
Graubard, B, Janout, V, Ruterbusch, JJ, Beebe-Dimmer, J, Cote, ML, Shuch, B, Mates, D,
Hofman, JN, Foretova, L, Rothman, N, Szeszenia-Dabrowska, N, Matveev, V, Wacholder, S,
Zaridze, D, Linehan WM, Brennan, P, Chow, WH. An investigation of risk factors for renal cell
carcinoma by histologic subtype in two case-control studies. Int J Cancer. 2013. 1;132(11):26407.
32. Shuch, B, Ricketts, CJ, Vocke, C, Valera, V, Gautam, R, Gupta, G, Middleton, L, Pinto, P,
Srinivasan, R, Merino, M, Bratslavsky, G, WM Linehan. Adrenal Hyperplasia as part of the
Hereditary Leiomyomatosis and Renal Cell Cancer Phenotype. J Urol. 2013, 189(2):430-5
33. Vourganti, S, Harbin, A, Singer, EA, Shuch B, Metwalli AR, Agarwal, PK. Low Grade
Micropapillary Urothelial Carcinoma, Does it Exist? – Low Grade Micropapillary Urothelial
Carcinoma, Does It Exist? - Analysis of Management and Outcomes from the Surveillance,
Epidemiology and End Results (SEER) Database. Journal Cancer. 2013 May 6;4(4):336-42
34. Hoffman, JN, Lan Q, Cawthon, R, Hosgood, HD, Shuch, B, Moore, LE, Rothman, N, Chow,
WH, Purdue, MP. A prospective study of leukocyte telomere length and risk of renal cell
carcinoma. Cancer Epidemiol Biomarkers Prev. 2013 May;22(5):997-1000
35. Shuch B, Hofmann, J, Vourganti, S, Nix, J, Linehan, WM, Purdue, M, Merino, MJ, Chow, WH.
Pathologic Validation of the Surveillance Epidemiology and End Result (SEER) Program for
Renal Cell Carcinoma. Urologic Oncology. 2014, 32(1):23.e9-13.
36. Shuch B, Ricketts, CJ, Kauffman, E, Komiya, T, Merino, M, Linehan, WM, Dennis, P, Cowden
Syndrome/ PTEN Harmatoma Tumor Syndrome: An Underappreciated Form of Hereditary
Kidney Cancer. J Urol. 2013, 190(6):1990-8.
37. Shuch, B., Hanley, J., Lai, J., Vourganti, S., Kim, S. P., Setodji, C. M., et al. (2013). Overall
survival advantage with partial nephrectomy: A bias of observational data? Cancer, 119(16),
2981–2989.
6
Brian Shuch, MD
38. Siddiqui, MM, Rais-Bahrami, S, Truong, H, Stamatakis, L, Vourganti, S, Nix, J, Hoang, AN,
Walton-Diaz, A, Shuch, B, Weintraub, M, Turkbey, B, Choyke, PL, Wood, BJ, Pinto, PA.
Gleason Score Upgrading Seen in MRI/Ultrasound Fusion Guided Prostate Biopsy Versus
Standard Prostate Biopsy Versus Standard 12-Core TRUS Biopsy. European Urology, 2013,
64(5):713-9.
39. Stamatakis, L, Siddiqui, MM, Logan, J, Nix, J, Rais-Bahrami, S, Walton-Diaz, A, Hoang, AN,
Vourganti, S, Truong, H, Shuch, B, Turkbey, B, Choyke, PL, Wood, BJ, Simon, R, Pinto, P.
Accuracy of Multiparametric Magnetic Resonance Imaging in Confirming Eligibility for Active
Surveillance for Men with Prostate Cancer. Cancer. 2013,119(18):3359-66.
40. Shuch, B, Agochukwu, N, Ricketts, CJ, Vocke, C, Merino, M, Linehan, WM, Srinivasan, R.
Vascular Endothelial Growth Factor Receptor-Targeted Therapy in Succinate Dehydrogenase C
Kidney Cancer, Journal of Clinical Oncology, 2016, 20;34(9):e76-9.
41. Truong H, Logan J, Turkbey B, Siddiqui MM, Rais-Bahrami S, Hoang AN, Pusateri C, Shuch B,
Walton-Diaz A, Vourganti S, Nix J, Stamatakis L, Harris C, Chua C, Choyke PL, Wood BJ, Pinto
PA. MRI characterization of the dynamic effects of 5α-reductase inhibitors on prostate zonal
volumes. Can J Urol. 2013 20(6):7002-7.
42. Shuch, B, Vourganti, S, Ricketts, CJ, Middleton, L, Peterson, J, Merino, M, Metwalli, AR,
Srinivasan, R, Linehan WM. Defining early-onset kidney cancer: Implications for germline and
somatic mutation testing and clinical management. Journal of Clinical Oncology. 2014,
32(5):431-7.
43. Jilaveanu, LB, Shuch, B, Zito, C, Parisi, F, Barr, M, Kulger, Y, Chen, L, Kluger, HM. PD-L1
Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of
Metastases. Journal of Cancer. 2014, 24;5(3):166-72.
44. Hoffman, JN, Hosgood, HD 3rd, Liu, CS, Chow, WH, Shuch, B, Cheng, WL, Lin, TT, Moore,
LE, Lan, Q, Rothman, N, Purdue, MP. A nested case-control study of leukocyte mitochondrial
DNA copy number and renal cell carcinoma in the Prostate, Lung, and Colorectal and Ovarian
Cancer Screening Trial. Carcinogenesis, 2014, 35(5):1028-31.
45. Shuch B, Hanley JM, Lai JC, Vourganti S, Setodji CM, Dick AW, Chow WH, Saigal CS;
Urologic Diseases in America Project. Adverse health outcomes associated with surgical
management of the small renal mass. J Urol. 2014 Feb;191(2):301-8
46. Shuch, B, Amin, A, Armstrong, A, Eble. JN, Ficarra, V, Lopez-Beltran, Martignoni, Rini, B,
Kutikov, A. Understanding Pathological Variants of Renal Cell Carcinoma: Distilling Therapeutic
Opportunities from Biological Complexity. European Urology, 2015. Jan;67(1):85-97.
47. Davis, CF, Ricketts, CR, Wang, M, Yang, L, Cherniak, AD, Shen, H, Buhay, C, Kang, H, Kim,
SC, Fahey, CC, Hacker, KE, Bhanot, G, Gordenin, DA, Chu, A, Guanaratne, PH, Biehl, M, Seth,
S, Kaipparettu, BA, Bristow, CA, Donehower, LA, Wallen, EM, Smith, AB, Tickoo, SK,
Tamboli, P, Reuter, V, Schmidt, LS, Hsieh, JJ, Choueiri, TK, Hakimi, AA, The Cancer Genome
Atlas Research Network, Chin, L, Meyerson, M, Kucherlapati, R, Park, WY, Robertson, AG,
Laird PW, Henske, EP, Kwiatkowski, DJ, Park, PJ, Morgan, M, Shuch, B, Munzy, D, Wheeler,
DA, Linehan,, WM, Gibbs, RA, Rathmell, WK, Creighton, CJ. The somatic genomic landscape of
Chromophobe Renal Cell Carcinoma, Cancer Cell. 2014 Sep 8;26(3):319-30.
48. Barr, M. L., Jilaveanu, L. B., Camp, R. L., Adeniran, A. J., Kluger, H. M., & Shuch, B. (2014).
PAX-8 expression in renal tumours and distant sites: A useful marker of primary and metastatic
renal cell carcinoma? J Clin Pathol. 2015 68(1):12-7
49. Hofmann, JN, Corley, DA, Zhao, Schneider, JL, Colt, JS. Shuch, B, Chow, W-H, Purdue, MP. An
investigation of renal cell carcinoma risk factors across racial and ethnic groups in a large
integrated health care system. Epidemiology. 2015, 26(1):59-67.
7
Brian Shuch, MD
50. Martucci VL, Lorenzo ZG, Weintraub M, Del Rivero J, Ling A, Merino M, Siddiqui M, Shuch B,
Vourganti S, Linehan WM, Agarwal PK, Pacak K. Association of urinary bladder paragangliomas
with germline mutations in the SDHB and VHL genes. Urol Oncol. 2015. Apr;33(4):167.e13-20
51. Shuch, B, Falbo, R, Parisi, F, Adeniran, A, Kluger, Y, Kluger, H, Jilaveanu, MET Expression in
Primary and Metastatic Clear Cell Renal Cell Carcinoma: Implications of Correlative Biomarker
Assessment to MET Pathway Inhibitors. BioMed Res Intl. 2015:192406.
52. The Cancer Genome Atlas Consortium. Comprehensive Molecular Characterization of Papillary
Renal Cell Carcinoma. New England Journal of Medicine, 2016, 14;374(2):135-45.
53. Zuoquan, X, Lee, YH, Boeke, M, Jilaveanu, LB, Bottaro, DP, Kluger, HM, Shuch, B. MET
Inhibition in Clear Cell Renal Cell Carcinoma J of Cancer. 2016, 18;7(10):1205-14.
54. Bi, M, Zhao, S, M, Zuoquan, X, Nawaf, C, Boeke, M, Belldegrun, AS, Pantuck, AJ, Valera, V,
Kluger, H, Adebowale A, Merino, M, Said, J, Lifton, R, Shuch, B. Genomic Characterization of
Sarcomatoid Transformation in Renal Cell Carcinoma, Proceedings of the National Academy of
Sciences, 23;113(8):2170-5.
55. .Booth L, Shuch B, Albers T, Roberts JL, Tavallai M, Proniuk S, Zukiwski A, Wang D, Chen CS,
Bottaro D, Ecroyd H, Lebedyeva IO, Dent P. Multi-kinase inhibitors can associate with heat
shock proteins through their NH2-termini by which they suppress chaperone function.
Oncotarget. 2016. ePub Feb 12.
56. Chen. F, Zhang, Y, Senbabaoglu, Y, Ciriello, G, Lixing Yang, L, Reznik, E, Shuch, B, Micevic,
G, De Velasco, G, Shinbrot, E, Noble, M, Lu, Y, Covington, KR, Xi, L, Drummond, J, Muzny, D,
Kang, H, Lee, J, Tamboli, P, Reuter, V, Shelly, CS, Kaipparettu, BA, Bottaro, DP, Godwin, AK,
Gibbs, RA, Getz, G, Kucherlapati, R, Park, PJ, Sander, C, Henske, EP, Zhou, JH, Kwiatkowski,
DJ, Ho, TH, Chouieri, TK, Hsieh, JJ, Akbani, R, Mills, GB, Hakimi, AA, Wheeler, DA,
Creighton, CJ. Multilevel Genomics-based Taxonomy of Renal Cell Carcinoma. Cell Reports,
2016, 14(10):2476-89
57. Mafolasire, A, Yao, X, Nawaf, C, Suarez-Sarmiento, A, Chow, WH, Zhao, W, Corley, D,
Hofmann, JN, Purdue, M, Adeniran, AJ, Shuch, B. Racial disparities in renal cell carcinoma: a
single-payer healthcare experience. Cancer Med. 2016, 5(8):2101-8.
58. Xie, Z., Lee, Y. H., Boeke, M., Jilaveanu, L. B., Liu, Z., Bottaro, D. P., Kluger, H.M, Shuch, B.
(2016). MET Inhibition in Clear Cell Renal Cell Carcinoma. Journal of Cancer, 7(10), 1205–
1214.
59. Syed, J., Wu, C, Nguyen, K, Cost, N, Siddiqui, M, Hittleman, A, Shuch, B. Distinguishing
Pediatric and Adolescent Renal Cell Carcinoma from Other Renal Malignancies. Pediatric Blood
& Cancer, (Accepted for publication).
Chapters, Books, and Reviews:
60. Shuch BM, Lam JS, Belldegrun AS, Figlin RA. Prognostic factors in renal cell carcinoma. Semin
Oncol. 2006, 33: 563-75.
58. Shuch B, Lam JS, Belldegrun AS. Open partial nephrectomy for the treatment of renal cell
carcinoma. Curr Urol Rep. 2006, 7:31-8.
59. Shuch, B, Belldegrun AS, Complications of Adrenal Surgery, In: Complications of Urologic
Surgery and Practice: Diagnosis, Prevention, and Management. Ed: Loughlin, KR, Informa
Healthcare, London, 2007, Volume 1
60. ASCO GU Cancer Symposium 2008: “Brain Metastasis from Renal Cell Carcinoma:
Presentation, Recurrence, and Survival.”
61. Shuch, B, Belldegrun AS, Figlin, RA, Carbonic Anhydrase IX: Biology and Clinical Approaches.
In: Renal Cell Carcinoma: Molecular Targets and Clinical Applications, Ed: Bukowski, Figlin,
and Atkins. Humana Press Inc., Totowa, 2008, Volume 2
8
Brian Shuch, MD
62. Shuch, B, La Rochelle, JC, Pantuck AJ, Belldegrun, AS, Staging in Renal Cell Carcinoma.
Current Opinions in Urology. 2008, 18(5):455-461
63. Klatte, T, Lam, JS, Shuch, B, Belldegrun, AS, Pantuck, AJ, Surveillance for renal cell carcinoma:
Why and how? When and how often? Urologic Oncology 2008, 26(5):550-4.
64. Shuch, B, Li, Z, Belldegrun, AS, CAIX and RCC: Prognosis and Response To Systemic Therapy,
BJU Int, 2008, 101 Suppl 4:25-30.
65. Shuch, B, Pantuck AJ, Belldegrun AS, Prognostic Factors in Localized Renal Cell Carcinoma. In:
Renal Cell Carcinoma, Ed: Campbell, S, Rini, B, 2008, Volume 1
66. La Rochelle, JC, Shuch, B, Belldegrun, AS. Urologic Surgery, In: Schwartz General Surgery, Ed:
2009, Volume 9.
67. Belldegrun, AS, Shuch B. (2009). Management of Locally Advanced Renal Cell Carcinoma. In:
Grunberg, SM, 2009 Genitourinary Cancers Symposium Proceeding Book. pp 70-71. Alexandria,
VA:ASCO.
68. ASCO GU Cancer Symposium 2009: “Cytoreductive Nephrectomy for Patients with Advanced
Kidney Cancer and Sarcomatoid Histology.”
69. Finley, DS, Shuch, B, Pantuck, AJ. Clinical Signs, Symptoms, and Paraneoplastic Syndromes of
Renal Cell Carcinoma, In: Comprehensive Textbook of Genitourinary Oncology, Vogelzang, NJ,
Scardino, PT, Zelefsky, MJ, Linehan, WM, 2010, 4th Edition.
70. Shuch, B, Finley, DS, Belldegrun, AS, Prognostic Factors in RCC In: Comprehensive Textbook
of Genitourinary Oncology, Vogelzang, NJ, Scardino, PT, Zelefsky, MJ, Linehan, WM, 2010, 4th
Edition.
71. Shuch, B*, Pouliot, F*, LaRochelle, JC, Pantuck, AJ, Belldegrun, AS. Contemporary
Management of Renal Tumors with Venous Tumor Thrombus. J of Urol. 2010. 184 (3):833-841.
72. Society of Urologic Oncology Winter Meeting 2011: “Adrenal Hyperplasia as part of the
Hereditary Leiomyomatosis and Renal Cell Cancer Phenotype.”
73. Shuch, B, Linehan, WM, Bratslavsky, G. Repeat Rartial Nephrectomy: Surgical, Functional and
Oncological Outcomes. Curr Opin Urol. 2011 Sep;21(5):368-75.
74. Finley, DS, Pouliot, F, Shuch, B, Chin, AI, Pantuck, A, DeKernion, KB, Belldegrun, AS.
Ultrasound-based combination therapy: potential in urologic cancer. Expert Rev Anticancer Ther.
2011 vol. 11 (1) pp. 107-13.
75. Finley, DS, Pouliot, F, Chin, AI, Shuch, B, Pantuck, A, Belldegrun AS, DeKernion, JB.
Immunological therapy in urological malignancy: Novel combination strategies. Int J Urol. 2011,
18(2):94-101.
76. Vourganti, S, Shuch, B, Bratslavsky, G. Optimal Management of Large Renal Tumors. Expert
Reviews in Anti-Cancer Therapy. 2011, 11(12):1889-1900.
77. Shuch, B, Bratslavsky, G, Srinivasan, R. Sarcomatoid RCC: A Comprehensive Review of the
Biology and Current Treatment Strategies. The Oncologist, 2012; 17(1):46-54.
78. Shuch, B, Singer, E, Bratslavsky. The Surgical Approach to Multifocal Renal Cancers:
Hereditary Syndromes, Ipsilateral Multifocality and Bilateral Tumors. Urologic Clinics of North
America, 2012, 39(2): 133-148.
79. Shuch, B, Linehan WM, von Hippel-Lindau Syndrome In: Clinical Genomics: Practical
Applications in Adult Patient Care. Stewart, D. 2012, 1st Edition.
80. Shuch, B, Pinto, P, Familial and Hereditary Syndromes In: Renal Cancer: Contemporary
Management. Libertino, J. 2012, 1st Edition
81. ASCO GU Cancer Symposium 2013: “Defining Early-Onset Kidney Cancer: Implications for
Age-Based Genetic Counseling”
82. Shuch, B, Linehan, WM, Srinivasan, R. Aerobic glycolysis: a Novel Target in Kidney Cancer.
Expert Reviews in Oncology. 2013, 13(6):711-719.
9
Brian Shuch, MD
83. Agochukwu, N, Shuch, B. Clinical Management of Renal Cell Carcinoma with Venous Tumor
Thrombus. World Journal of Urol. 2014, 32(3):581-9.
84. Shuch, B, Ricketts, CJ, Metwalli, AR, Pacak, K, Linehan, WM. The Genetic Basis of
Pheochromocytoma and Paraganglioma: Implications for Management. Urology. 2014,
83(6):1225-1332.
85. Agochukwu, N, Shuch, B. Renal Mass Biopsy. In: Interventional Urologic Oncology. Ed. Pinto,
P, Rastinhad, A, Seigal, D. Springer Publishing, 2015, 1st Edition.
86. Pan, S, Shuch, B. Hereditary Kidney Cancer. In: Renal Cell Cancer: Principles and Practice.
Springer Publishing, 2015, 1st Edition.
87. Adebowale, A, Shuch B, Humphrey, P. Hereditary Renal Cell Carcinoma Syndromes: Clinical,
Pathologic, and Genetic Features, American Journal of Surgical Pathology (In Press, 2015)
88. Kilchevsky A, Schulam, P, Shuch, B. Surgical Extirpation and Focal Ablation as Salvage
Therapy After Primary Treatment. In: Handbook of Focal Therapy for Prostate and Renal Cancer.
Ed. Johansen, Greene, Breen & Mouraviev, 2016, 1st Edition.
89. Leung, C, Pan, S, Shuch, B. Management of RCC in Young Patients and Patients with Hereditary
Syndromes. Current Opinions in Urology, 2016, 26(5):396-404.
Invited Editorials and Commentaries:
90. Shuch, B, Belldegrun AS, Words of Wisdom Re: Efficacy of Sunitinib and Sorafenib in
Metastatic Papillary and Chromophobe Renal Cell Carcinoma. European Urology, 2008,
53(5):1085-1086
91. Shuch, B, Pantuck, AJ, Editorial Comment: Serum CAIX Detection: Are we approaching the
“PSA Era” of Kidney Cancer? J Urol, 2008, 180:513-514.
92. Shuch, B, Belldegrun, AS: Editorial Comment: Response of the Primary Tumor to Neoadjuvant
Sunitinib in Patents with Advanced Renal Cell Carcinoma, J Urol 2009.
93. Brawer MK, Loeb S, Partin AW, Yoshimura N, Chancellor MB, Roehrborn CG, Assimos DG,
Nickel JC, Shuch B, Pouliot F, Belldegrun AS, Shapiro E. Best of the 2009 AUA Annual
Meeting: Highlights from the 2009 Annual Meeting of the American Urological Association,
April 25-30, 2009, Chicago, IL. Reviews in Urology. 2009, 11(2)101-103.
94. Shuch, B, Belldegrun AS, What’s New In Advanced Kidney Cancer. Timely Topics in Urology.
Reuter Thompson, 2010
95. Shuch, B, Pacek, K, Linehan, WM, Bratslavsky, G. Editorial Comment: Prediction of Malignant
Pheochromocytoma. J Urol. 2011,185(5): 1589-90.
96. Shuch, B, Sarcomatoid RCC: The Challenge of Understanding and Developing Treatment
Strategies for An Aggressive Variant of Kidney Cancer. Kidney Cancer Journal, Jan 2012.
97. Shuch, B, Linehan, WM, Kidney Cancer: Is Incomplete Renal Ablation Linked to Tumor
Progression? Nature Reviews Urology 2012. 9(10):547-548.
98. Shuch, B, Genetic Testing and Management in Early-Onset Kidney Cancer. Kidney Cancer
Journal. July, 2014.
99. Agarwal N, Shuch B, Pal SK, Up-front Targeted Therapy Prior to Cytoreductive Nephrectomy in
Treatment-Naïve Patients With Metastatic Renal Cell Carcinoma. JAMA Oncology. (ePub June
2nd, 2016).
Practice Guidelines, Standards and Consensus Statements:
10
Brian Shuch, MD
100. Shuch B, Klatte, T, Pantuck A, Surveillance for metastatic disease after nephrectomy for renal
cell carcinoma, UptoDate, Volume 15.2, 2013
101. Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK,
Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine
EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG,
Ryan CJ, Sheinfeld J, Shuch B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R. Kidney
cancer, version 3.2015.J Natl Compr Canc Netw. 2015 Feb;13(2):151-9.
102. Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK,
Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine
EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG,
Ryan CJ, Sheinfeld J, Shuch B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R.Testicular
Cancer, Version 2.2015. J Natl Compr Canc Netw. 2015 Jun;13(6):772-99.
Case Reports, Technical Notes, Letters:
103. Shuch B, Triaca, V, Raz, S. Leiomyoma of the perineum. Journal of Pelvic Medicine and
Surgery, 2007, 13:3, 145.
104. Shuch, B, Breda, A, Schulam, P. Laparoscopic Resection of an Exophytic, Enhancing Renal
Mass: A Case Report of Left-Sided Splenorenal Fusion. BJUI Online 2011.
105. Shuch, B, Humphrey, PA, Seminoma in Cryptorchid Testis in Prune Belly Syndrome. 2015, J
Urol Sep;194(3):799-800.
Grant Support:
NCI/K08 Grant
Funding Period: 9/1/2016-8/30/2020 PI: Brian Shuch
Title: Genomic Heterogeneity and the Small Renal Mass
This project involves assessment of heterogeneity of small renal tumors assessing common prognostic
markers that can predict behavior including driver mutations, copy number alterations, and gene
expression profiles.
NCI/BIQSFP Grant
Funding Period: 7/1/2016-7/1/2019 PI: Brian Shuch
Title: A Biomarker Analysis of MET Alterations and Papillary Subtype in S1500: A Randomized, Phase
II trial of MET Inhibitors in Metastatic Papillary Kidney Cancer
This project involves assessment of integrated biomarkers in a large national Phase II trial investigating
MET inhibitors for papillary kidney cancer. The project involves assessment of MET alterations
(mutation, overexpression, and amplification) and papillary subtype as a predictive/prognostic
biomarker of response to MET inhibitor therapy.
KL2/YCCI Clinical Scholar Award
Funding Period 12/2015-11/2017 PI: Brian Shuch
Title: Immunohistochemical heterogeneity of the small renal mass
This project involves creating a novel tissue microarray with 8 tumor punches from small and large
tumors. A novel method of automated quantitative immunofluorescence is employed to characterize
protein expression of various markers of tumor aggressiveness.
Yale Cancer Center/Pilot Grant
Funding Period 10/2015-10/2016 PI: Brian Shuch
Title: Racial Disparities in Kidney Cancer Prognosis and Subtype
This project involves assessing survival outcomes, epidemiologic risk factors, and subtype distribution
of kidney cancer within the State of Connecticut. African American patients with kidney cancer will also
have DNA extracted to validate a specific risk variant genotype increasing risk of kidney cancer.
11
Brian Shuch, MD
AUA Research Scholar Award
Funding Period 7/2016-7/2018
PI: Brian Shuch
Title: Characterization of Mitochondrial Dysfunction in Renal Oncocytoma
This project involves evaluation of loss of complex I activity in renal oncocytoma and the affect on
cellular metabolism. Using a renal oncocytoma model, we evaluate activity the various complexes in the
electron transport chain as well as characterize cellular respiration. Also with inhibition of Complex I,
we determine if this is sufficient to cause the mitochondrial phenotype associated with this tumor type.
12